L-norvaline; norvaline; 6600-40-4; (S)-2-Aminopentanoic acid; (2S)-2-aminopentanoic acid; h-nva-oh; L-2-aminopentanoic acid; Norvaline, L-; (S)-2-Aminovaleric acid; L-2-aminopentanoate; L-2-Aminovaleric acid; 2S-amino-pentanoic acid; A70UKS48FE; CHEBI:18314; Valeric acid, 2-amino-; Pentanoic acid, 2-amino-; MFCD00064421; Norvaline (VAN); l-(+)-norvaline; NVA; UNII-A70UKS48FE; alpha-L-Aminopentanoic acid; NSC-203786; Pentanoic acid, 2-amino-, (S)-; L(+)-Norvaline; EINECS 229-543-3; NSC 203786; NORVALINE [MI]; NORVALINE [INCI]; NORVALINE [WHO-DD]; 2S-AMINOVALERIC ACID; SCHEMBL38405; (S)-2-amino-pentanoic acid; CHEMBL55612; L-Norvaline, arginase inhibitor; (S)-(+)-2-Aminopentanoic acid; DTXSID701018015; ZINC391821; CS-D1371; HY-Y0399; L-.ALPHA.-AMINOVALERIC ACID; BDBM50357215; LMFA01100041; AKOS006240270; DB04185; (2S)-2-aminopentanoic acid;L-Norvaline; AC-12879; AC-31149; AS-13576; AM20100599; N0686; EN300-66088; C01826; N-9040; A835303; Q418707; Z1033300662; 9555A1CC-4DD7-41F1-9133-98A0F33A16A6